Entity

Time filter

Source Type


Pustylnyak V.O.,Novosibirsk State University | Lisachev P.D.,Russian Academy of Sciences | Shtark M.B.,Institute of Molecular Biology and Biophysics | Epstein O.I.,OOO nPF mATERIA MEDICA HOLDING
Brain Research | Year: 2011

In the present study we investigated the regulation of S100B expression during tetanization-induced hippocampal long term potentiation, one of the best characterized forms of synaptic plasticity. Tetanization resulted in time-dependent change in S100B gene expression and protein content in hippocampal CA1 area. We analyzed the promoter region of the rat S100B gene and identified response elements for the tumor suppressor p53. ChIP assay revealed that p53 could bind to putative p53-binding sites of the S100B promoter. The time-dependent recruitment of p53 to its putative binding sites in the S100B gene promoter paralleled the time-course change of S100B mRNA and protein levels. Thus, these results strongly support the view that S100B gene may be a target of p53. Moreover, we demonstrated that the increase of S100B protein content was accompanied with the decrease of p53 protein content, and it seems that the decrease is regulated on post-translational level. Thus, our results may help to understand the physiological function of the p53-S100B-p53 loop in the process of synaptic plasticity. © 2011 Elsevier B.V. All rights reserved. Source


Lisachev P.D.,Russian Academy of Medical Sciences | Shtark M.B.,Russian Academy of Medical Sciences | Sokolova O.O.,Russian Academy of Medical Sciences | Pustylnyak V.O.,Russian Academy of Medical Sciences | And 2 more authors.
Cardiovascular Psychiatry and Neurology | Year: 2010

The interest in tissue- and cell-specific S100 proteins physiological roles in the brain remains high. However, necessary experimental data for the assessment of their dynamics in one of the most important brain activities, its plasticity, is not sufficient. We studied the expression of S100B, S100A1, and S100A6 mRNA in the subfield CA1 of rat hippocampal slices after tetanic and low-frequency stimulation by real-time PCR. Within 30min after tetanization, a 2-4 fold increase of the S100B mRNA level was observed as compared to the control (intact slices) or to low-frequency stimulation. Subsequently, the S100B mRNA content gradually returned to baseline. The amount of S100A1 mRNA gradually increased during first hour and maintained at the achieved level in the course of second hour after tetanization. The level of S100A6 mRNA did not change following tetanization or low-frequency stimulation. Source


Gavrilova E.S.,OOO nPF mATERIA MEDICA HOLDING | Bobrovnik S.A.,Ukrainian Academy of Sciences | Sherriff G.,Ab Biotechnology Ltd | Myslivets A.A.,OOO nPF mATERIA MEDICA HOLDING | And 2 more authors.
PLoS ONE | Year: 2014

Selection of a suitable assay to measure the activity of drug agents based on release-active forms of anti-interferon-gamma antibodies (RA forms of Abs) is an important step forward in the investigation of such agents. In this study, the enzymelinked immunosorbent assay was utilized to examine the effect of RA forms of Abs specific for human interferon gamma on the interaction between monoclonal anti-interferon gamma antibodies and recombinant human interferon gamma. The experimental data and the results obtained by using relevant mathematical analysis showed that such RA forms of Abs are able to modulate the monoclonal antibody interaction with both soluble and immobilized (to the assay plate well) interferon gamma. These data demonstrated the importance of using relatively low concentrations of both soluble and plate-immobilized interferon gamma to detect the effects of RA forms of Abs to interferon gamma on the binding of monoclonal antibodies to interferon gamma. It has been suggested that the observed influence of RA forms of Abs on 'antibody-antigen' interaction could be used to detect and analyze the activity of drugs containing RA forms of Abs. © 2014 Gavrilova et al. Source


Nicoll J.,Zen-Bio, Inc. | Gorbunov E.A.,OOO nPF mATERIA MEDICA HOLDING | Tarasov S.A.,OOO nPF mATERIA MEDICA HOLDING | Epstein O.I.,OOO nPF mATERIA MEDICA HOLDING
International Journal of Endocrinology | Year: 2013

Purpose. To investigate the mechanism of action in peripheral tissues of novel complex drug containing release-active dilutions of antibodies to the beta subunit of the insulin receptor and antibodies to endothelial nitric oxide synthase (Subetta), which has shown efficacy in animal models of diabetes. Methods. Human mature adipocytes were incubated either with Subetta, with one of negative controls (placebo or vehicle), with one of nonspecific controls (release-active dilutions of antibodies to cannabinoid receptor type I or release-active dilutions of rabbit nonimmune serum), or with dimethyl sulfoxide (DMSO) at 37°C in a humidified incubator at 5% COfor three days. Rosiglitazone was used as reference drug. Secretion of adiponectin was measured by quantitative enzyme-linked immunosorbent assay (ELISA). Results. Only Subetta significantly stimulates adiponectin production by mature human adipocytes. Nonspecific controls did not significantly affect adiponectin secretion, resulting in adiponectin levels comparable to background values of the negative controls and DMSO. Conclusion. Increasing adiponectin production in absence of insulin by Subetta probably via modulating effect on the beta subunit of the insulin receptor might serve as one of the mechanisms of the antidiabetic effect of this drug. These in vitro results give first insight on possible mechanism of action of Subetta and serve as a background for further studies. © 2013 Jim Nicoll et al. Source


Ganina K.K.,OOO nPF mATERIA MEDICA HOLDING | Dugina Y.L.,OOO nPF mATERIA MEDICA HOLDING | Zhavbert E.S.,OOO nPF mATERIA MEDICA HOLDING | Ertuzun I.A.,OOO nPF mATERIA MEDICA HOLDING | And 2 more authors.
Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova | Year: 2015

Objective. To reveal the effects of release-active antibodies to S100 protein in an animal model of multiple sclerosis. Material and methods. Sixty female Wistar rats, aged 12 weeks, were included in the study. The pathology was induced by subcutaneous injection of the spinal cord homogenate. Afterwards the rats received a water solution of release-active antibodies to S100 protein (2,5 ml/kg/day, tenoten) or distilled water intragastrically during 30 days. Intramuscular injections of glatiramer acetate (4 mg/kg/day, copaxone) were used as a positive control. Results and conclusion. Release-active antibodies to S100 protein enhanced the latency period of the disease, reduced its peak intensity and compensated the loss of body weight of the animals. The experimental drug effect was similar to the results of copaxone injections. © 2015, Media Sphera. All rights reserved. Source

Discover hidden collaborations